In the promptly evolving area of oncology research, precise and economical mutation screening is important for acquiring focused therapies. The KRAS solutions System plays a pivotal role During this landscape by providing in depth answers for KRAS mutation profiling and Investigation. KRAS mutations, present in roughly 95% of RAS-similar oncogenic